---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-025441"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2026-05-27T20:57:37+00:00"
generated_at: "2026-05-27T20:59:51.975548+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Dermata shareholders approve 2021 equity plan increase to 402,214 shares

## Summary
- Elected David Hale, Steven Mento Ph.D., and Brittany Bradrick as Class II directors.
- Ratified CBIZ CPAs P.C. as independent auditor for FY2026.
- Approved issuance of shares underlying warrants (exceeding 20% of outstanding common stock).
- Approved repricing of warrants exercisable for up to 120,734 common shares.
- Approved adjournment proposal to allow sufficient votes on other proposals.

## SEC filing metadata
- accession: 0001493152-26-025441
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2026-05-27T20:57:37+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000149315226025441/0001493152-26-025441-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000149315226025441/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-025441
- JSON: https://secwatch.observer/filing/0001493152-26-025441.json
- Plain text: https://secwatch.observer/filing/0001493152-26-025441.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.